New findings suggest that a PSA level of 0.2 ng/mL or greater can predict a poor prognosis and indicate a possible need for ...

Understand every aspect of the global economy – and know how to make your next move.

Soros Fund Management's 13F portfolio grew slightly to $6.70B in Q1 2025. Check out the significant new stakes and major ...

An AstraZeneca Plc affiliate suffered a greater than $180 million court loss Wednesday over its lackluster efforts to ...

Cancer researchers discovered how exercise really can be like a drug for colon cancer, and AstraZeneca's immunotherapy drug ...

RSV monoclonal antibody, clesrovimab,” which was approved by the FDA yesterday, Leerink Partners LLC analyst Daina Graybosch said. Insmed Inc.’s chair and CEO, Will Lewis, called the phase IIb trial ...

A talk with study author on a new combination of acimtamig and an allogeneic natural killer cell product that shows safety and promising objective response rates in patients with few treatment choices ...

Databricks also announced updates to its Unity Catalog that expand support for Apache Iceberg — the open-source table format ...

The Computer Weekly Developer Network went to AeraHUB 25 London this week, a “decision intelligence event” hosted by Aera, an ...

AstraZeneca Plc said a handful of patients with lupus went into remission after getting an experimental treatment, as the UK ...

Looking at licensing deals struck in the past 10 years, Jefferies found that many Big Pharmas do not ultimately follow ...

The Scorpion Therapeutics spinoff sold rights for two EGFR inhibitors to Pierre Fabre Laboratories and is hoping to become a clinical-stage firm by 2026.